SCHEMBL8041168

SCHEMBL8041168

Cc1c(N)ccc(NCCc2c[nH]c3ccccc23)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.56
HTR1A P08908 2/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
HTT P42858 1/20 0.56
CDK2 P24941 11/20 0.55
DRD2 P14416 1/20 0.52
HTR7 P34969 1/20 0.52
HTR6 P50406 1/20 0.52
MC5R P33032 1/20 0.51
MC3R P41968 1/20 0.51
MC1R Q01726 1/20 0.51
KMT2A Q03164 2/20 0.51
POLB P06746 1/20 0.51
SLC2A1 P11166 1/20 0.51
RAD52 P43351 1/20 0.51
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8048284 0.85 HTR2A (0.56) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL18783078 0.82 HTR2A (0.56) HTR2ACDK2KMT2AMEN1
SCHEMBL17464549 0.81 CDK2 (0.55) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL18531442 0.80 ALDH1A1 (0.60) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL8030584 0.80 CDK2 (0.50) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL18531470 0.80 MAPT (0.64) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL18531467 0.80 CDK2 (0.56) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL28384834 0.79 HTR2A (0.66) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL8044543 0.78 HTR2A (0.54) HTR2AHTR1AKDM4EALDH1A1HTT
SCHEMBL8265777 0.78 ALDH1A1 (0.69) HTR2AHTR1AKDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2023-02-21 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
WO-2009037308-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885HTR1A 2675/4885KDM4E 3293/4885
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885HTR1A 2675/4885KDM4E 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.